Newton, Massachusetts, November 11, 2024— Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced that Alex Martin, Chief Executive Officer, will present at the following investor conferences. Stifel 2024 Healthcare Conference: Presentation on November 18, 2024, at 3:00 pm

 READ MORE

Newton, Massachusetts, August 29, 2024— Abcuro, Inc., a clinical stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced that Alex Martin, Chief Executive Officer, will present at the following investor conferences. Morgan Stanley 22nd Annual Global Healthcare Conference: Presentation on September 5, 2024,

 READ MORE

Newton, Massachusetts, July 31, 2024— Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced the appointment of Sarah Boyce to its Board of Directors. Ms. Boyce brings more than 25 years of global commercial leadership experience in the life

 READ MORE

Newton, Massachusetts, June 25, 2024— Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced the completion of enrollment of the registrational Phase 2/3 MUSCLE clinical trial evaluating ulviprubart (ABC008) for the treatment of inclusion body myositis (IBM). “We continue

 READ MORE

Newton, Massachusetts, December 6, 2023— Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced the appointment of Mark Pruzanski, M.D., as Chairman of its Board of Directors. Dr. Pruzanski brings more than 30 years of experience as

 READ MORE

Newton, Massachusetts, November 13, 2023 – Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced initiation of Part B of the registrational Phase 2/3 MUSCLE clinical study, an ongoing clinical trial of ulviprubart (ABC008) for the treatment

 READ MORE

Financing co-led by Redmile Group and Bain Capital Life Sciences Proceeds to support completion of Phase 2/3 registrational trial of ABC008, a first-in-class anti-KLRG1 antibody for the treatment of inclusion body myositis as well as continued development of additional clinical programs Newton, Massachusetts, August 17, 2023 – Abcuro, Inc., a clinical-stage biotechnology company developing therapies

 READ MORE

Company expects to have a Data Safety and Monitoring Board (DSMB) review by the end of this year  Newton, Massachusetts, May 31, 2023 – Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced completion of enrollment of the

 READ MORE

T-LGLL is an autoimmune disorder characterized by cytotoxic T lymphocytes which attack neutrophils and red blood cell precursors Newton, Massachusetts, October 4, 2022 – Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced initiation of a Phase

 READ MORE

 Industry veteran brings extensive experience in building and leading biopharmaceutical companies Newton, Massachusetts, October 3, 2022 – Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced the appointment of Alex Martin as Chief Executive Officer. He brings to

 READ MORE

Newton, Massachusetts, June 23, 2022– Abcuro, Inc., a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced that Dietmar Berger, M.D., Ph.D., currently the Chief Medical Officer and Head of Global Development at Sanofi will contribute his considerable experience to the company’s Board of

 READ MORE

Industry veteran brings extensive clinical development experience in immunology, immuno-oncology, and rare diseases to  leadership team Newton, Massachusetts, June 21, 2022– Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced the appointment of H. Jeffrey Wilkins, M.D.,

 READ MORE

Newton, Massachusetts, June 7, 2022, Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced the presentation of additional clinical results from its ongoing Phase 1 clinical trial of its lead product candidate ABC008 in patients with inclusion

 READ MORE